东诚药业(002675) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 850.50 million, a decrease of 3.32% compared to CNY 879.74 million in the same period last year[42]. - Net profit attributable to shareholders was CNY 50.11 million, down 8.77% from CNY 54.92 million year-on-year[42]. - The net cash flow from operating activities was CNY -92.82 million, a significant decline of 282.87% compared to CNY 50.76 million in the previous year[42]. - The net profit for the current period is ¥62,914,975.09, a decrease from ¥66,193,178.35 in the previous period, representing a decline of approximately 4.3%[62]. - The total comprehensive income for the current period is ¥60,401,256.33, down from ¥63,838,402.00 in the previous period, indicating a decrease of about 3.8%[62]. - The basic and diluted earnings per share for the current period are both ¥0.0608, compared to ¥0.0685 in the previous period, reflecting a decline of approximately 10.1%[63]. - The company reported a decrease in sales revenue from cash received for goods sold and services provided, totaling ¥836,066,401.59, down from ¥857,253,309.29 in the previous period[63]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 8,264.59 million, an increase of 1.07% from CNY 8,176.85 million at the end of the previous year[42]. - The company's equity attributable to shareholders was CNY 4,792.97 million, reflecting a 0.93% increase from CNY 4,748.66 million year-on-year[42]. - The total current assets as of March 31, 2023, amounted to CNY 3,230,853,874.60, an increase from CNY 3,192,720,273.08 at the beginning of the year[58]. - The inventory balance increased to CNY 1,196,891,591.38 from CNY 1,078,053,484.87 at the beginning of the year[58]. - The total non-current assets were reported at CNY 2,257,000,000.00 as of March 31, 2023[58]. - The company reported a decrease in long-term equity investments to CNY 79,017,999.22 from CNY 86,616,680.24[58]. - The total liabilities as of March 31, 2023, were CNY 1,500,000,000.00, reflecting a stable financial position[58]. Cash Flow - Cash received from other operating activities increased by 134.53% year-on-year, mainly due to increased deposits received from market expansion in formulations[22]. - Cash received from investment decreased by 78.88% year-on-year, primarily due to a reduction in the maturity of wealth management products[23]. - Cash paid for investments decreased by 61.54% year-on-year, mainly due to a reduction in the purchase of wealth management products[24]. - The net cash flow from operating activities is negative at ¥92,824,560.09, a significant drop from a positive cash flow of ¥50,759,287.12 in the previous period[63]. - Cash inflow from operating activities totaled ¥909,740,103.97, while cash outflow was ¥1,002,564,664.06, resulting in a net cash outflow of ¥92,824,560.09[63]. - The net cash flow from investing activities is negative at ¥148,998,267.71, compared to a negative cash flow of ¥127,163,054.98 in the previous period[64]. - Cash inflow from financing activities is ¥128,300,000.00, while cash outflow is ¥23,562,226.66, leading to a net cash inflow of ¥104,737,773.34[64]. - The ending cash and cash equivalents balance is ¥785,354,287.20, an increase from ¥636,286,441.06 in the previous period[64]. - Cash and cash equivalents decreased to CNY 868,286,731.45 from CNY 1,021,623,576.58 at the beginning of the year[58]. Expenses - Sales expenses increased by 30.48% year-on-year, driven by increased market expenses in the formulation and nuclear medicine business[19]. - Financial expenses increased by 31.07% year-on-year, primarily due to exchange rate impacts resulting in foreign exchange losses[20]. - The company experienced a 90.24% decrease in cash paid for debt repayment, indicating reduced bank loan repayments[50]. - The company reported a 43.72% increase in management expenses, primarily due to costs associated with equity acquisitions[46]. - Other income increased by 299.55%, mainly due to an increase in government subsidies received[47]. Government Support and R&D - Government subsidies recognized in the current period totaled 9,589,346.86 RMB[5]. - The company’s subsidiary received approval for clinical trials of a new drug, indicating ongoing research and development efforts[28]. - The company received approval for a clinical trial of the drug 177 Lu-LNC1004, which will commence in Singapore[57]. Borrowings and Investments - Short-term borrowings increased by 33.70% compared to the beginning of the period, primarily due to increased bank loans[8]. - Trading financial assets increased by 151.92% compared to the beginning of the period, mainly due to the purchase of wealth management products[17].